猴 呬 厉
liked
Analyst Wamsi Mohan questions HP's earnings growth sustainability, citing reliance on share buybacks. He predicts further margin erosion in print due to strong competition from Japanese firms.
HP Inc. Stock Is Falling. Print Problems Aren't Going Away, Analyst Says. -- Barrons.com
2
猴 呬 厉
liked
Honeywell's dividend increase signifies a robust commitment to shareholder value, marking the 15th raise in 14 consecutive years. It aligns with strategic trends like automation, aviation's future, and energy transition, reflecting a positive growth outlook.
2
猴 呬 厉
liked
Hesai Group's high P/S ratio is supported by strong past revenue and expected growth, outshining the industry. This bullish investor outlook underscores the stock's robust valuation, diminishing fears of a sharp price drop soon.
2
猴 呬 厉
liked
Quanex's increasing ROCE and capital suggest effective reinvestment for higher returns, marking it a potential growth stock. A 64% return over five years shows market recognition.
1
猴 呬 厉
liked
China's economic policies spur gains in US and Chinese stocks, especially for firms with high sales in China, says Wells Fargo's Harvey.
1
猴 呬 厉
liked
JinkoSolar's low P/E reflects investors' pessimism about future earnings. Expect further P/E decline unless earnings outlook improves.
1
猴 呬 厉
liked
Analyst foresees bullish prospects for Nasdaq and Intercontinental Exchange, expecting growth fueled by acquisitions and market recovery. Cboe Global and CME Group face more restrained growth due to market challenges.
1
猴 呬 厉
liked
Andrew Lokay suggests the strike might significantly impact Harris' campaign, indicating waning union support for Democrats. He warns prolonged strike could push the White House to reconsider its stance.
1
猴 呬 厉
liked
KLA's stock looks overpriced, may deter buyers. Investors advised to wait for a dip due to volatility. Traders should consider selling, re-enter later. Caution urged due to warning signs.
1
猴 呬 厉
liked
Analysts view the absence of severe side effects and lack of black box warning on Bristol Myers Squibb's new drug as bullish indicators for its stock, hinting at strong market adoption.
1